Nanofàrmacs

新型细胞因子组合mRNA疫苗佐剂及其应用

Resumen de: CN120733023A

本发明提供了一种新型细胞因子组合mRNA疫苗佐剂及其应用，所述疫苗佐剂包括可电离脂质、胆固醇、磷脂、PEG衍生物，以及含有编码GM‑CSF和IL‑21基因序列的mRNA；其中，GM‑CSF和IL‑21的氨基酸序列分别如SEQ ID NO:1、2所示。将本发明所述新型细胞因子组合mRNA疫苗佐剂应用于疫苗的制备，组合的细胞因子在注射部位对DC的招募和调控促进了LNP递送和表达引发了强烈的抗肿瘤效应。具体的，通过协同作用通过对注射部位免疫微环境的建立提升了抗原被表达、识别和呈递并且促进了抗原的交叉提呈，DC细胞的激活和淋巴结的浸润促进了T细胞的活化，为肿瘤免疫治疗建立了强大了抗肿瘤效应和免疫记忆。

一种可精准质控的干细胞纳米囊泡及其应用

Resumen de: CN119530147A

The invention relates to a stem cell bioactive nano-vesicle with efficient inflammation regulation and tissue repair effects, the average particle size of the nano-vesicle is 100-350nm, the polydispersity index (PDI) is 0.05-0.40, and the expression rate of phosphatidylserine (PS) on the surface of the nano-vesicle is greater than 40%. According to the preparation method, stem cells are subjected to apoptosis induction, and then a programmed serial extrusion process is adopted to prepare the nano-vesicles. The nano vesicles are moderate in particle size, uniform in distribution and high in production efficiency, the preparation process is easy to operate, the quality is stable and controllable, and the nano vesicles have excellent technical effects in the aspects of repair and regeneration of inflammation injury type tissues and organs.

一种具有肿瘤能量代谢调控功能的自组装基因纳米药物及其制备方法和应用

Resumen de: CN120733055A

本发明公开了一种具有肿瘤能量代谢调控功能的自组装基因纳米药物及其制备方法和应用，属于纳米材料技术领域。本发明通过将光敏剂与阳离子聚合物偶联，形成基因递送载体，该复合物在特定光照条件下能够增强肿瘤细胞的凋亡效果；通过将光敏剂与siRNA结合，实现了多重治疗机制的协同作用，不仅能精准靶向肿瘤细胞并干预其能量代谢，还能在光照下增强细胞死亡效应，显著提高治疗效果。本发明通过靶向肿瘤细胞中高表达的与能量代谢相关的基因，并结合光动力疗法，解决了现有技术在肿瘤能量代谢干预方面的不足，有望在未来成为靶向细胞器的新型治疗手段，可用于抗癌、抗菌、抗炎等药物治疗及示踪。

经由穿膜肽进行非共价修饰脂质纳米颗粒缀合物及用途

Resumen de: CN120737148A

本发明提供了一种多肽衍生物，其具有结构式CnH2n+1CONH‑CPP‑COOH，其中，n=11，13，15，17；CPP为穿膜肽。本发明还提供了该多肽衍生物的制备方法和与脂质纳米颗粒缀合的用途。本发明通过加入在LNP配方中加入基于CPP的阳离子两亲性分子，由可电离脂质负责mRNA的内体释放而CPP促进LNP与细胞膜的结合，通过调整各组分组成比例以及电荷，显著提升了LNP在体内外的递送效率，经由TAT序列修饰LNP可使得肝脏体内递送效率提升20倍。

一种氨基酸阳离子脂质

Resumen de: CN117460710A

The invention provides a novel amino acid cationic lipid, the structure of which is shown in a general formula (1), and the definition of each symbol is consistent with that described in the specification. The amino acid cationic lipid is a pharmaceutically acceptable, biodegradable or high-biocompatibility lipid, and has the advantages of low toxicity, low immunogenicity and high biocompatibility. The amino acid or the amino acid derivative used in the preparation process is simple and easy to obtain, can be naturally obtained or simply synthesized, and has the advantages of simplicity, convenience, safety and production cost saving. Degradable groups can further be contained between amino acid residues and lipophilic tail chains of the novel amino acid cationic lipid, due to existence of the degradable groups, lipid nanoparticles LNP prepared from the novel amino acid cationic lipid can be degraded in vivo in good time, and the problems that in the prior art, LNP prepared from lipid which cannot be degraded can be stored in vivo, the endosome environment is acidified, and the lipid nanoparticles LNP cannot be degraded in vivo are solved. Endosome escape of drug molecules (such as nucleic acid) is blocked, and the problem that drugs delivered into cells cannot play a role is solved. # imgabs0 #

一种脂质纳米颗粒及其应用

Resumen de: CN120732814A

本发明涉及一种脂质纳米颗粒及其应用。所述脂质纳米颗粒包括：阳离子脂质、阴离子脂质DOPS（1,2‑二油酰基‑sn‑甘油‑3‑磷脂酰‑L‑丝氨酸）、其他脂质和靶向抗体。本发明经过研究发现，掺杂阴离子脂质DOPS并间接偶联靶向抗体可以显著提高纳米颗粒对脾脏T细胞的转染效率。本发明进一步将编码靶向肿瘤血管内皮细胞和肿瘤细胞的CAR蛋白的核酸装载在上述脂质纳米颗粒中并用于肿瘤治疗，结果上述治疗显著促进了免疫细胞的瘤内浸润，显著抑制多种实体瘤进展，为CAR‑T疗法在实体瘤中的有效应用提供了新思路、新手段。

一种用于金黄色葡萄球菌感染检测灭活的诊疗探针

Resumen de: CN120733070A

本发明公开了一种用于金黄色葡萄球菌感染检测灭活的诊疗探针，构建方法包括：S1：双波长激发量子点的制备；S2：量子点@ZIF‑8的制备，在量子点表面进行PSS修饰，后在ZIF‑8包覆过程中在1小时内匀速缓慢滴加2‑甲基咪唑溶液用以控制纳米颗粒的成核速率，并且加入PVP稳定纳米粒子的形成；S3：量子点@ZIF‑8@Ber的制备，在合成过程中将小檗碱加入溶剂中，采用一锅法直接合成得到负载小檗碱的量子点@ZIF‑8材料。本发明利用夹心法对金黄色葡萄球菌进行检测，结果通过荧光检测仪反馈，并且可以连接手机进行智能化监测，简便快捷；利用抗原抗体反应，靶向捕获金黄色葡萄球菌，其余细菌的影响很小。

一种氨基酸阳离子脂质

Resumen de: CN117460710A

The invention provides a novel amino acid cationic lipid, the structure of which is shown in a general formula (1), and the definition of each symbol is consistent with that described in the specification. The amino acid cationic lipid is a pharmaceutically acceptable, biodegradable or high-biocompatibility lipid, and has the advantages of low toxicity, low immunogenicity and high biocompatibility. The amino acid or the amino acid derivative used in the preparation process is simple and easy to obtain, can be naturally obtained or simply synthesized, and has the advantages of simplicity, convenience, safety and production cost saving. Degradable groups can further be contained between amino acid residues and lipophilic tail chains of the novel amino acid cationic lipid, due to existence of the degradable groups, lipid nanoparticles LNP prepared from the novel amino acid cationic lipid can be degraded in vivo in good time, and the problems that in the prior art, LNP prepared from lipid which cannot be degraded can be stored in vivo, the endosome environment is acidified, and the lipid nanoparticles LNP cannot be degraded in vivo are solved. Endosome escape of drug molecules (such as nucleic acid) is blocked, and the problem that drugs delivered into cells cannot play a role is solved. # imgabs0 #

一种用于治疗急性呼吸窘迫综合征的仿胞葬纳米制剂

Resumen de: CN120732785A

本发明公开了一种用于治疗急性呼吸窘迫综合征的仿胞葬纳米制剂，属于生物医药技术领域。本发明的仿胞葬纳米制剂包括活性成分、脂质体磷脂双分子层和靶头，所述活性成分由ROS清除药物和抗炎药物组成。本发明创新性地运用仿胞葬作用实现纳米制剂的高效精准靶向，在脂质体表面修饰凋亡细胞标志物，通过释放“eat me”信号，模拟巨噬细胞清除凋亡细胞的天然生物学过程被肺泡巨噬细胞识别并吞噬，实现高效特异性靶向，同时炎症部位巨噬细胞PS受体表达上调进一步增强了靶向效果，为急性呼吸窘迫综合征药物制剂高效递送及病理微环境的重塑提供了一种新的途径。

一种氨基酸阳离子脂质

Resumen de: CN117460710A

The invention provides a novel amino acid cationic lipid, the structure of which is shown in a general formula (1), and the definition of each symbol is consistent with that described in the specification. The amino acid cationic lipid is a pharmaceutically acceptable, biodegradable or high-biocompatibility lipid, and has the advantages of low toxicity, low immunogenicity and high biocompatibility. The amino acid or the amino acid derivative used in the preparation process is simple and easy to obtain, can be naturally obtained or simply synthesized, and has the advantages of simplicity, convenience, safety and production cost saving. Degradable groups can further be contained between amino acid residues and lipophilic tail chains of the novel amino acid cationic lipid, due to existence of the degradable groups, lipid nanoparticles LNP prepared from the novel amino acid cationic lipid can be degraded in vivo in good time, and the problems that in the prior art, LNP prepared from lipid which cannot be degraded can be stored in vivo, the endosome environment is acidified, and the lipid nanoparticles LNP cannot be degraded in vivo are solved. Endosome escape of drug molecules (such as nucleic acid) is blocked, and the problem that drugs delivered into cells cannot play a role is solved. # imgabs0 #

编码治疗性多肽的核酸及包含所述核酸的脂质纳米颗粒组合物

Resumen de: WO2024199114A1

Provided are lipid nanoparticle compositions comprising nucleic acids encoding RSV antigenic polypeptides. Also provided are novel antigenic RSV-F polypeptides as well as nucleic acids encoding the antigenic RSV-F polypeptides.

一种基于Mn-DNA纳米疫苗的肿瘤免疫治疗方法

Resumen de: CN120733013A

本发明涉及一种基于Mn‑DNA纳米疫苗的肿瘤免疫治疗方法。本发明提供一种用于肿瘤免疫治疗的纳米颗粒，其包含金属离子Mn2+、外源dsDNA、抗原肽和打靶肽。本发明还提供制备所述纳米颗粒的方法、包含所述纳米颗粒的疫苗或药物组合物以及它们用于肿瘤免疫治疗的用途等。本发明的纳米颗粒能够被精准递送到抗原提呈细胞，促进抗原提呈细胞成熟，增强抗原递呈能力，显著增强肿瘤靶向性和抗肿瘤活性。本发明所用原料在体内均可降解，生物安全性高。

一种罗汉果外泌体样纳米颗粒及其制备方法和在改善肠道健康产品中的应用

Resumen de: CN120732915A

本发明公开一种罗汉果外泌体样纳米颗粒及其制备方法和在改善肠道健康产品中的应用，将罗汉果果肉与预冷PBS匀浆，离心取上清液，经超速离心获得粗提液；通过羧基化磁珠偶联磷脂酰丝氨酸靶向多肽，构建免疫磁珠层析柱，特异性捕获并纯化外泌体样纳米颗粒；所得纳米颗粒具有优异的生物相容性和安全性，可显著调节肠道菌群平衡、增强肠道屏障功能、抑制肠道炎症；本发明为肠道疾病治疗及功能性食品开发提供了天然、高效的新方案，具有广阔的医药和食品应用前景。

一种负载葛花异黄酮的纳米颗粒及其制备方法和应用

Resumen de: CN120732816A

本发明公开了一种负载葛花异黄酮的纳米颗粒及其制备方法和应用，属于复合纳米颗粒技术领域。本发明的负载葛花异黄酮的纳米颗粒，包括纳米颗粒中心和多糖外壳；纳米颗粒中心为包覆葛花异黄酮的酒糟醇溶蛋白，多糖外壳由内至外依次为硫酸葡聚糖外壳和壳聚糖外壳。其制备方法包括以下步骤：以碳酸钠为牺牲模版制备负载葛花异黄酮的单层纳米颗粒；通过调节溶液pH，使纳米粒子带正电，以静电沉积效应涂覆负电性的硫酸葡聚糖外壳；然后与壳聚糖溶液混合，进一步涂覆正电性的壳聚糖外壳，形成层层自组装结构。本发明的负载葛花异黄酮的纳米颗粒在体外模拟消化环境中释放率更高，清除自由基活性更强，为葛花异黄酮的递送提供了更高效的技术。

一种生物合成虾青素的马氏副球菌及其色素提取物和应用

Resumen de: CN120738011A

本发明公开了一种生物合成虾青素的马氏副球菌及其色素提取物和应用。该马氏副球菌（Paracoccus marcusii）IHA069于2022年7月15日保藏于中国普通微生物菌种保藏中心，保藏编号为CGMCC No.25302，16s rDNA序列如SEQ ID No.1所示。通过发酵培养基培养48h后，离心并采用无水乙醇萃取菌体得到色素提取物，虾青素在色素提取物中的比例达到40%。马氏副球色素提取物为主料，玉米淀粉、吐温‑80、氯化钙水为配料，调和喷雾干燥得到具有抗氧化效果的纳米颗粒。相较于IHA034，IHA069强化了提高了虾青素产量便于工业生产，提高了在不同动物中使用的可行性。本发明采用纳米颗粒包埋技术提高了色素提取物中虾青素的保留率，提高了保存温度和有效时间。

MRNA BASED ENZYME PRECURSOR AND PREPARATION METHOD THEREOF

Resumen de: WO2025203087A1

The present disclosure discloses a recombinant construct including a vector and a recombinant nucleic acid molecule (1). The vector including at least one promoter region (13). The recombinant nucleic acid molecule (1) is encoded at least by SEQ ID No. 1. The recombinant nucleic acid molecule (1) is disposed downstream of the at least one promoter region (13) to enable transcription of the recombinant nucleic acid molecule (1) by the promoter region (13) to a plurality of messenger ribonucleic acid (mRNA) molecules encoded by SEQ ID No. 9.

RNA FORMULATION

Resumen de: WO2025202360A1

The present invention relates to aqueous RNA compositions that are suitable for storage, comprising Tris, a saccharide, and phosphate anions. The present invention also relates to methods of producing such aqueous RNA compositions, as well as their use in therapy and prevention of infectious diseases.

LIPID NANOPARTICLE LOADED WITH ANTITUMORAL AGENT AND FUNCTIONNALIZED TO TARGET IMMOSUPPRESSIVE CELLS

Resumen de: WO2025202213A1

The present invention relates to lipid nanoparticle loaded with antitumoral agent and functionalized to target immunosuppressive cells. Inventors developpe valrubicin-loaded immunoliposomes (Val-ILs). A small amount of valrubicin incorporated into Val-ILs induces leukemia cell death in vivo, suggesting that Val-ILs could be used to treat acute leukemia cells. Inventors also demonstrated that Val-ILs could reduce the risk of contamination of CD34+ hematopoietic stem cells by acute leukemia cells during autologous peripheral blood stem cell transplantation. They also highlighted the potential of Val-ILs to target immunosuppressive cell populations in the spleen. The most efficient Val-ILs were found to be those loaded with CD11b,CD223, CD64, TIM1, CD200R3, CD204, CD49b, VEGFR2 and SIGLECF antibodies. This study provides the effectiveness and ease of preparation of Val-ILs as a novel nanoparticle technology. In the context of cancers, Val-ILs have the potential to be used as a precise and effective therapy based on targeted vesicle-mediated cell death.

FORMULATIONS FOR ADMINISTERING LAAM, norLAAM AND dinorLAAM AND METHODS OF THEIR USE TO TREAT OPIOID USE DISORDER

Resumen de: US2025302751A1

Rapid-release formulations for administering Levo-alpha-acetylmethadol (LAAM), norLAAM and dinorLAMM and, optionally, magnesium, are provided. The formulations include solid i) core-shell oral dosage forms delivered in capsules or tablets, and ii) electrospun nano/microfiber buccal film dosage forms. Methods of the use of the formulations to treat opioid use disorder (OUD) and pain are also provided.

TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS USING NANO POLYMERS OF HISTONE DEACETYLASE INHIBITORS

Resumen de: US2025302767A1

Provided are compositions that include a histone deacetylase inhibitor (HDACi) encapsulated in and/or otherwise associated with a nanoparticle. In some embodiments, the HDACi is romidepsin, vorinostat, belinostat, panobinostat, and/or chidamide. In some embodiments, the nanoparticle is a poly(D,L-lactide)-PEG-methyl ether (mPEG-PDLLA) nanopolymer. Also provided are methods for treating diseases, disorders, and/or conditions associated with sensitivity to histone deacetylase inhibitors, such as but not limited to tumors and/or cancers; and methods for inhibiting the growth, proliferation, and/or metastasis of a tumor and/or a cancer associated with sensitivity to histone deacetylase inhibitors by administering an effective amount of a composition as disclosed herein, which methods can optionally include administering at least one additional therapeutically active agent, such as but not limited to a chemotherapeutic agent.

IMMUNE ENGINEERING AMPLIFICATION

Resumen de: US2025302763A1

This disclosure provides methods of increasing in vivo transfection efficiency and pharmacologic activity of T cells, by administering multiple small doses within a compact time period of T cell-targeted lipid nanoparticles encapsulating mRNA encoding an antigen receptor that recognizes an antigen of a cell against which immune activity is to be directed. Also provided are methods of depleting B cells, and methods of treating B cell-mediated diseases and disorders by depleting B cells and achieving immunological reset, entailing administration of immune cell-targeted lipid nanoparticles encapsulating mRNA encoding an antigen receptor recognizing a B cell marker as multiple small doses within a compact time period. The antigen receptor can be a T cell receptor or a chimeric antigen receptor.

FORMULATIONS FOR ORAL DELIVERY OF POLYPEPTIDES, ANTIBODIES AND PROTEINS AND USES THEREOF

Resumen de: US2025302766A1

Provided is a nanoparticle comprising a composition comprising a polypeptide having a molecular weight greater than 50,000 g/mol (e.g. IgY antibodies), wherein the composition is encapsulated in a material that includes a biocompatible bioerodible polymer. Also provided is a method of preparing these nanoparticles, and use of the nanoparticles as a therapeutic to treat a disease condition.

SOLID LIPID NANOPARTICLES FOR ENCAPSULATION AND DELIVERY OF BIOACTIVE COMPOUNDS AND METHODS OF MAKING THE SAME

Resumen de: US2025302764A1

Solid lipid nanoparticles (SLNs) for delivery of bioactive compounds are disclosed. The SLNs comprise a lipid matrix and surfactant layer encapsulating at least one bioactive compound selected from vitamins, minerals, enzymes, algae-derived bioactives, proteins, peptides, amino acids, antioxidants, small synthetic molecules, plant-derived volatile compounds, or botanical extracts. The SLNs exhibit submicron particle size, low polydispersity, and sufficient surface charge to ensure colloidal stability and efficient delivery. In one embodiment, algae-based bioactives, such as phycocyanin or fucoxanthin, are encapsulated using only natural and sustainable lipids and surfactants to improve bioavailability and support environmentally friendly formulations. The SLNs may be formulated for oral, topical, transdermal, injectable, ophthalmic, mucosal, textile, veterinary, or agricultural administration. Applications include human and animal health, functional foods, skincare, nutrient supplementation, and crop treatment. The disclosed SLNs offer a biocompatible and scalable delivery system that protects sensitive compounds, enables sustained release, and enhances absorption across diverse industries.

TRIACETYL ANDROGRAPHOLIDE NANOCRYSTAL AND PREPARATION METHOD AND APPLICATION THEREOF

Resumen de: US2025302765A1

The triacetyl andrographolide nanocrystal is mainly composed of triacetyl andrographolide, a stabilizer and an excipient, and an average particle size of drug particles in a triacetyl andrographolide nanocrystal suspension obtained by redissolving the triacetyl andrographolide nanocrystal in water, is less than 500 nm, and a PDI is less than 0.2. The nanocrystal suspension is prepared from the triacetyl andrographolide and the stabilizer by a high-speed shear anti-solvent method in combination with a high-pressure homogenization method, then the excipient is added, and the nanocrystal is prepared through spray-drying.

SELF-EMBEDDING SILVER NANOPARTICLE BIOMASS WASTE COMPOSITIONS

Nº publicación: US2025302769A1 02/10/2025

Solicitante:

THE US SECRETARY OF AGRICULTURE [US]
The United States of America, as represented by the Secretary of Agriculture

Resumen de: US2025302769A1

Compositions and methods of making and using silver nanoparticles embedded in biomass waste matrixes of various types is described. Exemplified compositions include a silver nanoparticle embedded in a cotton gin waste nanofiber composite. Compositions and methods of making and using aerogels comprising silver nanoparticles in cotton gin waste nanofiber are described. Exemplified uses of compositions include use as antimicrobial agents.